← All trials
NCT05584007
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Nov 1, 2024
- Completion date
- Dec 1, 2025
- First posted
- Oct 18, 2022
- Last posted
- Oct 18, 2022
- Enrollment
- 356
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Moorgreen Hospital, SouthamptonLead sponsor
- University of East AngliaCollaborator
- University of East AngliaCollaborator
- University of NottinghamCollaborator
- Moorgreen Hospital, SouthamptonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.